uniQure N.V. (NASDAQ:QURE) Receives Consensus Rating of “Moderate Buy” from Brokerages

uniQure N.V. (NASDAQ:QURE) has earned an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $65.00.

Several brokerages have weighed in on QURE. Wolfe Research raised shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research report on Wednesday, July 29th. Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Royal Bank Of Canada upped their price objective on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a research note on Wednesday, June 17th. Finally, Mizuho increased their target price on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th.

uniQure Price Performance

QURE opened at $47.06 on Friday. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of -11.74 and a beta of 0.92. uniQure has a 1 year low of $8.73 and a 1 year high of $71.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The stock’s 50 day simple moving average is $40.82 and its 200 day simple moving average is $27.71.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same quarter in the prior year, the business posted ($0.69) EPS. As a group, analysts predict that uniQure will post -3.74 earnings per share for the current year.

Insider Activity at uniQure

In other news, insider Walid Abi-Saab sold 30,000 shares of uniQure stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider directly owned 148,235 shares in the company, valued at approximately $6,881,068.70. This trade represents a 16.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 164,429 shares of uniQure stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the completion of the sale, the chief executive officer owned 558,810 shares in the company, valued at approximately $24,766,459.20. This represents a 22.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 388,229 shares of company stock worth $16,817,099 over the last 90 days. 4.65% of the stock is owned by insiders.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Hennion & Walsh Asset Management Inc. raised its stake in uniQure by 107.3% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company’s stock worth $6,546,000 after buying an additional 73,566 shares in the last quarter. Kalehua Capital Management LLC bought a new stake in uniQure during the 1st quarter valued at approximately $4,760,000. UBS Group AG boosted its position in uniQure by 139.7% during the 4th quarter. UBS Group AG now owns 491,454 shares of the biotechnology company’s stock valued at $11,760,000 after acquiring an additional 286,465 shares in the last quarter. Voss Capital LP grew its holdings in shares of uniQure by 68.0% during the 4th quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company’s stock worth $5,025,000 after acquiring an additional 85,000 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of uniQure by 37.2% during the 4th quarter. Jennison Associates LLC now owns 1,371,190 shares of the biotechnology company’s stock worth $32,813,000 after acquiring an additional 371,706 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.